Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck ditches oncolytic virus Cavatak

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 04, 2022 2:42pm

255 Views

Post# 35149649

RE:RE:RE:RE:Merck ditches oncolytic virus Cavatak

Yes to your thoughts on AMBUSH; speaks loudly for pela.

Offering the 2 Phase 3 Trials as a unit tells me they are on the right path. I think events have overtaken affairs and a multitude of pathways have opened up. There is not much separating the players in terms of the potential benefits of Pelareorep, and how this ends is anyone's guess

I am holding very tightly, and wish all concerned, especially the patients, success.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario